EVRA should not be used in women who currently have the following conditions: Thrombophlebitis, thromboembolic disorders.
A past history of deep vein thrombophlebitis or thromboembolic disorders.
Known thrombophilic conditions.
Cerebrovascular or coronary artery disease.
Valvular heart disease with complications.
Persistent blood pressure values of ≥ 160 mm Hg systolic or ≥ 100 mm Hg diastolic.
Diabetes with vascular involvement.
Migraine with focal aura.
Known or suspected carcinoma of the breast.
Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia.
Undiagnosed abnormal genital bleeding.
Cholestatic jaundice of pregnancy or jaundice with prior hormonal contraceptive use.
Acute or chronic hepatocellular disease with abnormal liver function.
Hepatic adenomas or carcinomas.
Known or suspected pregnancy.
Hypersensitivity to any component of this product.
Concomitant use with the medicinal products containing ombitasvir/paritaprevir/ritonavir and dasabuvir (see Precautions and Interactions).